REG - Destiny Pharma PLC - Notice of R&D Update Meeting

Destiny PharmaAnnouncement

22/09/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220922:nRSV1976Aa&default-theme=true

RNS Number : 1976A  Destiny Pharma PLC  22 September 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Notice of R&D Update Meeting

 

Brighton, United Kingdom - 22 September 2022 - Destiny Pharma plc
(AIM:DEST), a clinical stage biotechnology company focused on the development
of novel medicines to prevent life threatening infections, today announces
that it will host an R&D Update meeting for analysts and investors on
Tuesday, 18 October 2022 at 1.00 pm BST / 8.00 am EST.

The R&D Update meeting will be held in person at finnCap Ltd, 1
Bartholomew Close, London, EC1A 7BL, with the option of virtual attendance via
the Investor Meet platform.

The meeting, which is scheduled to last around two hours, will include an
update on the status of NTCD-M3 and XF-73, the Company's two lead clinical
programmes, by Dr Yuri Martina, Chief Medical Officer, and Dr Stephanie
Bewick, Chief Business Officer, as well as a short update on its earlier
pipeline assets.

In addition, there will be presentations by senior Key Opinion Leaders on:

·    Recurrence in C. difficile infection (CDI) - the unmet medical need
by Professor Mark Wilcox, Consultant Microbiologist and Head of R&D in
Microbiology at the Leeds Teaching Hospital and member of Destiny Pharma's
Scientific Advisory Board.

·    Surgical site infection in breast reconstruction surgery - a Plastic
Surgeon's view by Dr Alex Mericli, Associate Professor and Plastic Surgeon at
MD Anderson Cancer Center.

There will be an opportunity for Q&A with the speakers and Destiny
Pharma's management team.

Prior registration for the event is required. To attend in person please
contact RD@destinypharma.com (mailto:RD@destinypharma.com) . To attend
virtually, investors can sign up to Investor Meet Company for free, and add to
meet Destiny Pharma plc via:

https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor)

Investors who already follow Destiny Pharma plc on the Investor Meet Company
platform will automatically be invited to the event. Questions can be
submitted pre-event via the Investor Meet Company Dashboard up until 1.00 pm
BST /8.00 am EST the day before the meeting, or at any time during the live
presentation.

 

 

 

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus

+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com (mailto:Janhavi.Mohite@sternir.com)

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

For further information on the company, please visit
https://www.destinypharma.com (https://www.destinypharma.com) .

 

Notes to Editors

Mark H Wilcox, MD, FRCPath

Professor Mark Wilcox is an expert in infectious disease and currently serves
in several substantive roles including: a Consultant Microbiologist and Head
of Research and Development in Microbiology at the Leeds Teaching Hospitals
(LTHT).  Professor Wilcox is also the Infection Lead of Leeds NIHR Diagnostic
Technologies Medical Technology and In Vitro Diagnostic Co-operative;
Professor of Medical Microbiology at the University of Leeds; National
Clinical Director of AMR for NHS Improvement/England (NHSE/I); and Lead on
Clostridium difficile for Public Health England .

He serves in multiple advisory roles, including to UK SAGE (COVID-19), as
co-chair of the UK Technical Validation Group for COVID-19 tests, as a medical
advisor to the National Infection Prevention & Control Lead (NHSE/I), the
Medical Research Council's Infection and Immunity Panel, as Chair of PHE's
Rapid Review Panel  and member of the UK NHS Antimicrobial Resistance
Programme Board. Professor Wilcox was formerly the Director of Infection
Prevention (4 years), Infection Control Doctor (8 years), and Clinical
Director of Pathology (6 years) at LTHT and Head of Microbiology (15 years).

 

Dr Alex Mericli

Dr. Mericli is an Associate Professor of Plastic Surgery at The University of
Texas MD Anderson Cancer Center. He completed his plastic surgery residency at
the University of Virginia, followed by a fellowship in microvascular and
reconstructive surgery at MD Anderson. Dr. Mericli is interested in all
aspects of reconstructive surgery with particular attention to breast, head
and neck, and trunk reconstruction. He is dedicated to surgical research and
education, having received numerous awards and has authored or co-authored
over 70 peer-reviewed articles and book chapters on various plastic surgery
topics and lectured nationally and internationally on his research.

Dr. Mericli also serves as the Medical Director for Perioperative Surgical
Services at MD Anderson. In this role he leads a number of efforts and
strategies aimed at optimizing the efficiency of the main and Mays operating
rooms. Dr Mericli is a champion of value-based care - both in theory and in
practice - and has published a number of articles detailing the
cost-effectiveness of several different plastic surgery procedures and
technology.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBSGDCCSDDGDB